Novo Nordisk A/S (NYSE:NVO) Shares Sold by Harbour Capital Advisors LLC

Harbour Capital Advisors LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 11.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,649 shares of the company’s stock after selling 1,020 shares during the period. Harbour Capital Advisors LLC’s holdings in Novo Nordisk A/S were worth $670,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. International Assets Investment Management LLC increased its position in shares of Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares during the period. DSM Capital Partners LLC grew its holdings in Novo Nordisk A/S by 257,816.0% during the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after acquiring an additional 1,593,303 shares during the period. Mediolanum International Funds Ltd bought a new stake in Novo Nordisk A/S in the third quarter worth about $98,765,000. Marshall Wace LLP lifted its holdings in Novo Nordisk A/S by 34,472.1% in the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock valued at $98,696,000 after acquiring an additional 689,441 shares during the last quarter. Finally, Wellington Management Group LLP bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $42,017,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 2.2 %

Shares of NYSE NVO traded down $1.93 during mid-day trading on Monday, reaching $84.33. The company had a trading volume of 5,607,502 shares, compared to its average volume of 7,144,377. The stock has a fifty day moving average of $100.35 and a two-hundred day moving average of $119.04. Novo Nordisk A/S has a 12-month low of $81.50 and a 12-month high of $148.15. The company has a market capitalization of $378.43 billion, a price-to-earnings ratio of 27.29, a PEG ratio of 1.37 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Analyst Upgrades and Downgrades

Several research firms recently commented on NVO. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.